Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02612415
Other study ID # 14HC30
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received October 23, 2015
Last updated December 15, 2016
Start date November 2015
Est. completion date December 2016

Study information

Verified date December 2016
Source Great Ormond Street Hospital for Children NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

A feasibility study to inform the design and conduct of a randomised controlled trial of high flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in critically ill children


Description:

Breathing support is the most common intervention provided to critically ill children in a paediatric intensive care unit (PICU). Although invasive breathing support (delivered through a tracheal tube) is lifesaving, concerns regarding its risks (infection and lung damage) have prompted greater use of non-invasive respiratory support (NRS). However, there is little scientific evidence to guide PICU clinicians on the comparative effectiveness of the commonly used modes of NRS.

In this feasibility study, the investigators are testing whether it is possible to conduct a randomised clinical trial comparing two modes of NRS: continuous positive airway pressure (CPAP), which has been used for over two decades, and high flow nasal cannula (HFNC), a newer method of respiratory support. It is not known for sure how useful HFNC is in critically ill children because there is no published research comparing it with CPAP. However, since HFNC is easier to use and better tolerated by children, many hospitals are now using HFNC instead of CPAP. Before HFNC is widely adopted, a clinical trial to establish its role in the management of critically ill children is urgently needed.

As part of this study, the investigators will randomly allocate children deemed to require NRS by their treating clinician to either HFNC or CPAP. The investigators will mainly assess whether sufficient number of children can be recruited to the trial, whether clinicians are willing to randomise children, and test the proposed treatment pathways for CPAP and HFNC. The trial will run over six months, and recruit 120 sick children from three National Health Service (NHS) hospitals. Consent will be sought from parents/guardians for their children to be included in the study, usually before CPAP or HFNC is started, unless emergency life-saving treatment is required, in which case consent will be deferred until there is more time to discuss the study with parents/guardians.


Recruitment information / eligibility

Status Completed
Enrollment 121
Est. completion date December 2016
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender Both
Age group 36 Weeks to 15 Years
Eligibility Inclusion Criteria:

Eligible patients will fall into one of two groups:

Group A (Step-up)

1. Age >36 weeks corrected gestational age and <16 years, AND

2. Deemed to require non-invasive respiratory support by the treating clinician for an acute illness, AND

3. Satisfies one or more of the following criteria:

- Hypoxia (oxygen saturation <92% in fraction of inspired oxygen (FiO2) >0.40, or equivalent). FiO2 of 0.40 roughly equates to standard unhumidified nasal cannula oxygen delivered at 6 L/min or oxygen delivered via facemask without a rebreather bag at 6-10 L/min.

- Acute respiratory acidosis (pH <7.3 with a concomitant pCO2 >6.5 kPa)

- Moderate respiratory distress (use of accessory muscles, subcostal and intercostal recession, tachypnoea for age, grunting)

Group B (Step-down)

1. Age >36 weeks corrected for gestation and <16 years, AND

2. Deemed to require non-invasive respiratory support by the treating clinician after extubation, following a spell of invasive ventilation

- Either immediately after extubation as a 'planned' procedure, irrespective of clinical condition ('planned') OR

- Prompted by deterioration in clinical condition within 72 hours after extubation ('rescue'). Clinical parameters to assess the need for NRS in this situation will be similar to point 3 in Group A.

Exclusion Criteria:

1. Deemed by the treating clinician to require immediate intubation/invasive ventilation due to severe hypoxia, acidosis and/or respiratory distress, upper airway obstruction or recurrent apnoeas

2. Tracheostomy in place

3. Pre-existing air-leak syndrome (pneumothorax/pneumomediastinum)

4. Midfacial/craniofacial anomalies (unrepaired cleft palate, choanal atresia) or had recent craniofacial surgery

5. Agreed limitation of intensive care treatment plan in place ('not for intubation')

6. On domiciliary non-invasive ventilation prior to PICU admission

7. Managed on either HFNC and/or CPAP (or other form of non-invasive ventilation such as BiPAP) in the preceding 24 hours

8. Previously recruited to this study during the same PICU admission

9. Cannot be treated with HFNC

- Unavailability of appropriate sized nasal prongs

- Unavailability of HFNC device

10. Cannot be treated with CPAP

- Unavailability of right size of face mask, prong or other patient interface

- Unavailability of CPAP device

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula
A heated, humidified, HFNC device will be used to deliver a gas flow rate of 2 L/kg/min for the duration that the patient needs non-invasive respiratory support
Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure
CPAP will be provided using a set expiratory pressure of 6-8 cm water (H2O) pressure for the duration that the infant needs non-invasive respiratory support

Locations

Country Name City State
United Kingdom Barts Health NHS Trust London
United Kingdom Great Ormond Street Hospital for Children NHS Foundation Trust London
United Kingdom Imperial College Healthcare NHS Trust London

Sponsors (4)

Lead Sponsor Collaborator
Great Ormond Street Hospital for Children NHS Foundation Trust Barts & The London NHS Trust, Imperial College London, Intensive Care National Audit & Research Centre

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of eligible patients in Group A (step-up) and Group B (step-down) Baseline No
Primary Number of parents/guardians who refuse prospective or deferred consent Through study completion, an average of 24 hours No
Primary Randomising at least 50% of eligible patients Baseline No
Primary Proportion of patients adherent to the study treatment Through study completion, an average of 72 hours No
Primary Mean COMFORT score 72 hours No
Primary Number of parents completing the Parental Stressor Scale: PICU (PSS:PPICU) 24 hours No
Secondary Proportion of children randomised to the intervention or control who need intubation (Group A) or re-intubation (Group B) 72 hours No
Secondary Proportion of children randomised to the intervention or control who fail the assigned treatment and require either crossover or escalation to other forms of ventilation 72 hours No
Secondary Number of children who experience pre-specified adverse events (pneumothorax, pneumomediastinum, nasal or facial trauma, abdominal distension, nosocomial infection) during the period they are receiving non-invasive respiratory support 28 days Yes
Secondary Improvement in oxygenation, partial pressure of carbon dioxide (pCO2) levels, heart rate, respiratory rate, and work of breathing 24 hours No
Secondary Length of PICU and hospital stay, length of invasive ventilation, length of non-invasive support, ventilator-free days at day 28 through study completion, an average of 28 days No
Secondary Mortality at PICU discharge and at hospital discharge through study completion, an average of 28 days No
See also
  Status Clinical Trial Phase
Recruiting NCT04498598 - Structural Modification In Supraglottic Airway Device N/A
Completed NCT05532670 - N600X Low Saturation Accuracy Validation
Enrolling by invitation NCT04106401 - Intravascular Volumes in Hypoxia During Antarctic Confinement N/A
Recruiting NCT05883137 - High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill
Not yet recruiting NCT05817448 - Hypoxia-induced Autophagy in the Pathogenesis of MAP
Recruiting NCT02661152 - DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC. Phase 3
Terminated NCT02801162 - Evaluation of Accuracy and Precision of a New Arterial Blood Gas Analysis System Blood in Comparison With the Reference Standard N/A
Completed NCT02943863 - Regional Ventilation During High Flow Nasal Cannula and Conventional Nasal Cannula in Patients With Hypoxia N/A
Not yet recruiting NCT02201875 - Intrinsic Periodic Pattern of Breathing N/A
Completed NCT02105298 - Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study) N/A
Completed NCT01922401 - Inverse Ratio Ventilation on Bariatric Operation N/A
Active, not recruiting NCT01681238 - Goal-directed Therapy in High-risk Surgery N/A
Completed NCT01463527 - Using Capnography to Reduce Hypoxia During Pediatric Sedation N/A
Completed NCT01507623 - Value of Capnography During Nurse Administered Propofol Sedation (NAPS) N/A
Withdrawn NCT00638040 - The Gene Expression Studies of the Role of Tumor Microenvironments in Tumor Progression N/A
Active, not recruiting NCT06097754 - Intermittent Exogenous Ketosis (IEK) at High Altitude N/A
Completed NCT04589923 - The VISION-Acute Study
Completed NCT05044585 - Evaluation of RDS MultiSense® in Desaturation Analysis in Healthy Volunteers N/A
Completed NCT03659513 - The Effect of ECMO on the Pharmacokinetics of the Drugs and Their Clinical Efficacy
Completed NCT03221387 - Sleep and Daytime Use of Humidified Nasal High-flow Oxygen in COPD Outpatients N/A